title: Relapsed Hodgkin lymphoma: management strategies.
abstract: Although Hodgkin lymphoma (HL) is largely curable with first-line therapy, approximately one-third of patients will not have a complete response to frontline treatment or will subsequently relapse. Only 50% of these patients will be effectively salvaged with conventional therapies. The prognosis is particularly poor for those patients with chemotherapy refractory disease, who are unable to obtain even transient disease control, and for patients who relapse following high dose chemotherapy and autologous stem cell transplant. In this review, we summarize the most recent updates on the management of patients with relapsed HL, the role of novel therapies such as brentuximab vedotin, and an overview of promising new agents currently under investigation. We also discuss the role of consolidation strategies such as high-dose chemotherapy and autologous stem cell transplant, and reduced-intensity allogeneic hematopoietic stem cell transplant, and the need for new strategies in the elderly patient population.
authors.affiliation: Department of Medicine, New York University School of Medicine, NYU Cancer Institute, 240 East 38th Street, 19th Floor, New York, NY, 10016, USA.
authors.forename: Francesca
authors.initials: F
authors.lastname: Montanari
authors.forename: Catherine
authors.initials: C
authors.lastname: Diefenbach
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D064592:Autografts; D000079963:Brentuximab Vedotin; D006689:Hodgkin Disease / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D049268:Positron-Emission Tomography; D033581:Stem Cell Transplantation
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin